What resources are available to educate my patients on potential disease-related complications of their myeloma?

FAQ Library published on September 22, 2015
Download Transcript Download Audio
Ajay K. Nooka, MD, FACP
Assistant Professor
Division of Bone Marrow Transplant
Winship Cancer Institute of Emory University
Atlanta, Georgia

Welcome to Managing Myeloma. My name is Ajay Nooka. I am an assistant professor in the Division of Bone Marrow Transplant at the Winship Cancer Institute of Emory University. I am frequently asked, “What resources are available to educate my patients on potential disease-related complications of their myeloma?” Your doctor’s office is the first place to start. Your doctor should be able to provide educational resources for potential disease-related complications and probably a consultation with your pharmacist to educate on the potential therapy-related complications is needed. Very good clinical resources are available online at multiple websites such as the American Cancer Society and other online resources such as the educational tools at ManagingMyeloma.com, International Myeloma Foundation, and Multiple Myeloma Research Foundation, other ones are Association of Community Cancer Centers. These are all good websites where you can find potential disease-related complications of multiple myeloma. Other websites of significance are ASCO educational website (American Society of Clinical Oncology), or the Lymphoma & Leukemia Society should be good resources to get updated on the potential disease-related complications. Thank you for viewing this activity. For additional resources, please view other educational activities on ManagingMyeloma.com.

Reviewed on January 17, 2017 for clinical relevance.

Last modified: February 8, 2017
Related Items by Author
What are practical considerations in management of the most common AEs with monoclonal antibodies?
Ajay K. Nooka, MD, FACP
FAQ Library published on July 26, 2017
What are the practical considerations in management of the most common AEs in HDAC inhibitors?
Ajay K. Nooka, MD, FACP
FAQ Library published on July 19, 2017
What are practical considerations in management of the most common AEs with proteasome inhibitors?
Ajay K. Nooka, MD, FACP
FAQ Library published on July 12, 2017
What are the practical considerations in management of the most common adverse events with IMiDs?
Ajay K. Nooka, MD, FACP
FAQ Library published on July 5, 2017
Should patients with cardiac history receive carfilzomib?
Ajay K. Nooka, MD, FACP
FAQ Library published on June 14, 2017
What are the signs that my patient is non-adherent with their maintenance therapy?
Ajay K. Nooka, MD, FACP
FAQ Library published on September 10, 2015